Pharma & Healthcare
Postmenopausal Vaginal Atrophy Drugs - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
- Oct 12, 24
- ID: 163476
- Pages: 140
- Figures: 258
- Views: 10
Postmenopausal vaginal atrophy (PVA) is the type of condition of vaginal wall thinning the reduced level of estrogen causes that. The changes in the genitourinary tract arising from a hypoestrogenic state includes decreased vaginal vascularization, reduced vaginal lubrication, thinning of the vaginal epithelium. The pH level continuously increases and loss of lactobacilli microflora allows opportunistic colonization by pathogenic bacteria can produce infection.
The global market for Postmenopausal Vaginal Atrophy Drugs was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Postmenopausal Vaginal Atrophy Drugs, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Postmenopausal Vaginal Atrophy Drugs by region & country, by Type, and by Application.
The Postmenopausal Vaginal Atrophy Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Postmenopausal Vaginal Atrophy Drugs.
Market Segmentation
By Company
Pfizer Inc
Mylan NV
Novartis AG
Hikma Pharmaceuticals plc
Aurobindo Pharma
AbbVie Inc
Melinta Therapeutics, Inc
Bristol-Myers Squibb Company
GSK plc
Bayer AG
Lupin
Perrigo Company plc
Bionovo, Inc
TherapeuticsMD, Inc
Endoceutics, Inc
Segment by Type:
Topical Estrogen
Oral Estrogen
Other
Segment by Application
Online Pharmacy
Hospital Pharmacy
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Postmenopausal Vaginal Atrophy Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Postmenopausal Vaginal Atrophy Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Postmenopausal Vaginal Atrophy Drugs in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
The global market for Postmenopausal Vaginal Atrophy Drugs was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Postmenopausal Vaginal Atrophy Drugs, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Postmenopausal Vaginal Atrophy Drugs by region & country, by Type, and by Application.
The Postmenopausal Vaginal Atrophy Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Postmenopausal Vaginal Atrophy Drugs.
Market Segmentation
By Company
Pfizer Inc
Mylan NV
Novartis AG
Hikma Pharmaceuticals plc
Aurobindo Pharma
AbbVie Inc
Melinta Therapeutics, Inc
Bristol-Myers Squibb Company
GSK plc
Bayer AG
Lupin
Perrigo Company plc
Bionovo, Inc
TherapeuticsMD, Inc
Endoceutics, Inc
Segment by Type:
Topical Estrogen
Oral Estrogen
Other
Segment by Application
Online Pharmacy
Hospital Pharmacy
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Postmenopausal Vaginal Atrophy Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Postmenopausal Vaginal Atrophy Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Postmenopausal Vaginal Atrophy Drugs in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
1 Market Overview
1.1 Postmenopausal Vaginal Atrophy Drugs Product Introduction
1.2 Global Postmenopausal Vaginal Atrophy Drugs Market Size Forecast
1.2.1 Global Postmenopausal Vaginal Atrophy Drugs Sales Value (2019-2030)
1.2.2 Global Postmenopausal Vaginal Atrophy Drugs Sales Volume (2019-2030)
1.2.3 Global Postmenopausal Vaginal Atrophy Drugs Sales Price (2019-2030)
1.3 Postmenopausal Vaginal Atrophy Drugs Market Trends & Drivers
1.3.1 Postmenopausal Vaginal Atrophy Drugs Industry Trends
1.3.2 Postmenopausal Vaginal Atrophy Drugs Market Drivers & Opportunity
1.3.3 Postmenopausal Vaginal Atrophy Drugs Market Challenges
1.3.4 Postmenopausal Vaginal Atrophy Drugs Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Postmenopausal Vaginal Atrophy Drugs Players Revenue Ranking (2023)
2.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue by Company (2019-2024)
2.3 Global Postmenopausal Vaginal Atrophy Drugs Players Sales Volume Ranking (2023)
2.4 Global Postmenopausal Vaginal Atrophy Drugs Sales Volume by Company Players (2019-2024)
2.5 Global Postmenopausal Vaginal Atrophy Drugs Average Price by Company (2019-2024)
2.6 Key Manufacturers Postmenopausal Vaginal Atrophy Drugs Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Postmenopausal Vaginal Atrophy Drugs Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Postmenopausal Vaginal Atrophy Drugs
2.9 Postmenopausal Vaginal Atrophy Drugs Market Competitive Analysis
2.9.1 Postmenopausal Vaginal Atrophy Drugs Market Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by Postmenopausal Vaginal Atrophy Drugs Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Postmenopausal Vaginal Atrophy Drugs as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Topical Estrogen
3.1.2 Oral Estrogen
3.1.3 Other
3.2 Global Postmenopausal Vaginal Atrophy Drugs Sales Value by Type
3.2.1 Global Postmenopausal Vaginal Atrophy Drugs Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Postmenopausal Vaginal Atrophy Drugs Sales Value, by Type (2019-2030)
3.2.3 Global Postmenopausal Vaginal Atrophy Drugs Sales Value, by Type (%) (2019-2030)
3.3 Global Postmenopausal Vaginal Atrophy Drugs Sales Volume by Type
3.3.1 Global Postmenopausal Vaginal Atrophy Drugs Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global Postmenopausal Vaginal Atrophy Drugs Sales Volume, by Type (2019-2030)
3.3.3 Global Postmenopausal Vaginal Atrophy Drugs Sales Volume, by Type (%) (2019-2030)
3.4 Global Postmenopausal Vaginal Atrophy Drugs Average Price by Type (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Online Pharmacy
4.1.2 Hospital Pharmacy
4.2 Global Postmenopausal Vaginal Atrophy Drugs Sales Value by Application
4.2.1 Global Postmenopausal Vaginal Atrophy Drugs Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Postmenopausal Vaginal Atrophy Drugs Sales Value, by Application (2019-2030)
4.2.3 Global Postmenopausal Vaginal Atrophy Drugs Sales Value, by Application (%) (2019-2030)
4.3 Global Postmenopausal Vaginal Atrophy Drugs Sales Volume by Application
4.3.1 Global Postmenopausal Vaginal Atrophy Drugs Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global Postmenopausal Vaginal Atrophy Drugs Sales Volume, by Application (2019-2030)
4.3.3 Global Postmenopausal Vaginal Atrophy Drugs Sales Volume, by Application (%) (2019-2030)
4.4 Global Postmenopausal Vaginal Atrophy Drugs Average Price by Application (2019-2030)
5 Segmentation by Region
5.1 Global Postmenopausal Vaginal Atrophy Drugs Sales Value by Region
5.1.1 Global Postmenopausal Vaginal Atrophy Drugs Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Postmenopausal Vaginal Atrophy Drugs Sales Value by Region (2019-2024)
5.1.3 Global Postmenopausal Vaginal Atrophy Drugs Sales Value by Region (2025-2030)
5.1.4 Global Postmenopausal Vaginal Atrophy Drugs Sales Value by Region (%), (2019-2030)
5.2 Global Postmenopausal Vaginal Atrophy Drugs Sales Volume by Region
5.2.1 Global Postmenopausal Vaginal Atrophy Drugs Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global Postmenopausal Vaginal Atrophy Drugs Sales Volume by Region (2019-2024)
5.2.3 Global Postmenopausal Vaginal Atrophy Drugs Sales Volume by Region (2025-2030)
5.2.4 Global Postmenopausal Vaginal Atrophy Drugs Sales Volume by Region (%), (2019-2030)
5.3 Global Postmenopausal Vaginal Atrophy Drugs Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America Postmenopausal Vaginal Atrophy Drugs Sales Value, 2019-2030
5.4.2 North America Postmenopausal Vaginal Atrophy Drugs Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe Postmenopausal Vaginal Atrophy Drugs Sales Value, 2019-2030
5.5.2 Europe Postmenopausal Vaginal Atrophy Drugs Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific Postmenopausal Vaginal Atrophy Drugs Sales Value, 2019-2030
5.6.2 Asia Pacific Postmenopausal Vaginal Atrophy Drugs Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America Postmenopausal Vaginal Atrophy Drugs Sales Value, 2019-2030
5.7.2 South America Postmenopausal Vaginal Atrophy Drugs Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Sales Value, 2019-2030
5.8.2 Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Postmenopausal Vaginal Atrophy Drugs Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Postmenopausal Vaginal Atrophy Drugs Sales Value
6.2.1 Key Countries/Regions Postmenopausal Vaginal Atrophy Drugs Sales Value, 2019-2030
6.2.2 Key Countries/Regions Postmenopausal Vaginal Atrophy Drugs Sales Volume, 2019-2030
6.3 United States
6.3.1 United States Postmenopausal Vaginal Atrophy Drugs Sales Value, 2019-2030
6.3.2 United States Postmenopausal Vaginal Atrophy Drugs Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Postmenopausal Vaginal Atrophy Drugs Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Postmenopausal Vaginal Atrophy Drugs Sales Value, 2019-2030
6.4.2 Europe Postmenopausal Vaginal Atrophy Drugs Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Postmenopausal Vaginal Atrophy Drugs Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Postmenopausal Vaginal Atrophy Drugs Sales Value, 2019-2030
6.5.2 China Postmenopausal Vaginal Atrophy Drugs Sales Value by Type (%), 2023 VS 2030
6.5.3 China Postmenopausal Vaginal Atrophy Drugs Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Postmenopausal Vaginal Atrophy Drugs Sales Value, 2019-2030
6.6.2 Japan Postmenopausal Vaginal Atrophy Drugs Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Postmenopausal Vaginal Atrophy Drugs Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Postmenopausal Vaginal Atrophy Drugs Sales Value, 2019-2030
6.7.2 South Korea Postmenopausal Vaginal Atrophy Drugs Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Postmenopausal Vaginal Atrophy Drugs Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Postmenopausal Vaginal Atrophy Drugs Sales Value, 2019-2030
6.8.2 Southeast Asia Postmenopausal Vaginal Atrophy Drugs Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Postmenopausal Vaginal Atrophy Drugs Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Postmenopausal Vaginal Atrophy Drugs Sales Value, 2019-2030
6.9.2 India Postmenopausal Vaginal Atrophy Drugs Sales Value by Type (%), 2023 VS 2030
6.9.3 India Postmenopausal Vaginal Atrophy Drugs Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Pfizer Inc
7.1.1 Pfizer Inc Company Information
7.1.2 Pfizer Inc Introduction and Business Overview
7.1.3 Pfizer Inc Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2019-2024)
7.1.4 Pfizer Inc Postmenopausal Vaginal Atrophy Drugs Product Offerings
7.1.5 Pfizer Inc Recent Development
7.2 Mylan NV
7.2.1 Mylan NV Company Information
7.2.2 Mylan NV Introduction and Business Overview
7.2.3 Mylan NV Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2019-2024)
7.2.4 Mylan NV Postmenopausal Vaginal Atrophy Drugs Product Offerings
7.2.5 Mylan NV Recent Development
7.3 Novartis AG
7.3.1 Novartis AG Company Information
7.3.2 Novartis AG Introduction and Business Overview
7.3.3 Novartis AG Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2019-2024)
7.3.4 Novartis AG Postmenopausal Vaginal Atrophy Drugs Product Offerings
7.3.5 Novartis AG Recent Development
7.4 Hikma Pharmaceuticals plc
7.4.1 Hikma Pharmaceuticals plc Company Information
7.4.2 Hikma Pharmaceuticals plc Introduction and Business Overview
7.4.3 Hikma Pharmaceuticals plc Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2019-2024)
7.4.4 Hikma Pharmaceuticals plc Postmenopausal Vaginal Atrophy Drugs Product Offerings
7.4.5 Hikma Pharmaceuticals plc Recent Development
7.5 Aurobindo Pharma
7.5.1 Aurobindo Pharma Company Information
7.5.2 Aurobindo Pharma Introduction and Business Overview
7.5.3 Aurobindo Pharma Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2019-2024)
7.5.4 Aurobindo Pharma Postmenopausal Vaginal Atrophy Drugs Product Offerings
7.5.5 Aurobindo Pharma Recent Development
7.6 AbbVie Inc
7.6.1 AbbVie Inc Company Information
7.6.2 AbbVie Inc Introduction and Business Overview
7.6.3 AbbVie Inc Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2019-2024)
7.6.4 AbbVie Inc Postmenopausal Vaginal Atrophy Drugs Product Offerings
7.6.5 AbbVie Inc Recent Development
7.7 Melinta Therapeutics, Inc
7.7.1 Melinta Therapeutics, Inc Company Information
7.7.2 Melinta Therapeutics, Inc Introduction and Business Overview
7.7.3 Melinta Therapeutics, Inc Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2019-2024)
7.7.4 Melinta Therapeutics, Inc Postmenopausal Vaginal Atrophy Drugs Product Offerings
7.7.5 Melinta Therapeutics, Inc Recent Development
7.8 Bristol-Myers Squibb Company
7.8.1 Bristol-Myers Squibb Company Company Information
7.8.2 Bristol-Myers Squibb Company Introduction and Business Overview
7.8.3 Bristol-Myers Squibb Company Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2019-2024)
7.8.4 Bristol-Myers Squibb Company Postmenopausal Vaginal Atrophy Drugs Product Offerings
7.8.5 Bristol-Myers Squibb Company Recent Development
7.9 GSK plc
7.9.1 GSK plc Company Information
7.9.2 GSK plc Introduction and Business Overview
7.9.3 GSK plc Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2019-2024)
7.9.4 GSK plc Postmenopausal Vaginal Atrophy Drugs Product Offerings
7.9.5 GSK plc Recent Development
7.10 Bayer AG
7.10.1 Bayer AG Company Information
7.10.2 Bayer AG Introduction and Business Overview
7.10.3 Bayer AG Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2019-2024)
7.10.4 Bayer AG Postmenopausal Vaginal Atrophy Drugs Product Offerings
7.10.5 Bayer AG Recent Development
7.11 Lupin
7.11.1 Lupin Company Information
7.11.2 Lupin Introduction and Business Overview
7.11.3 Lupin Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2019-2024)
7.11.4 Lupin Postmenopausal Vaginal Atrophy Drugs Product Offerings
7.11.5 Lupin Recent Development
7.12 Perrigo Company plc
7.12.1 Perrigo Company plc Company Information
7.12.2 Perrigo Company plc Introduction and Business Overview
7.12.3 Perrigo Company plc Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2019-2024)
7.12.4 Perrigo Company plc Postmenopausal Vaginal Atrophy Drugs Product Offerings
7.12.5 Perrigo Company plc Recent Development
7.13 Bionovo, Inc
7.13.1 Bionovo, Inc Company Information
7.13.2 Bionovo, Inc Introduction and Business Overview
7.13.3 Bionovo, Inc Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2019-2024)
7.13.4 Bionovo, Inc Postmenopausal Vaginal Atrophy Drugs Product Offerings
7.13.5 Bionovo, Inc Recent Development
7.14 TherapeuticsMD, Inc
7.14.1 TherapeuticsMD, Inc Company Information
7.14.2 TherapeuticsMD, Inc Introduction and Business Overview
7.14.3 TherapeuticsMD, Inc Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2019-2024)
7.14.4 TherapeuticsMD, Inc Postmenopausal Vaginal Atrophy Drugs Product Offerings
7.14.5 TherapeuticsMD, Inc Recent Development
7.15 Endoceutics, Inc
7.15.1 Endoceutics, Inc Company Information
7.15.2 Endoceutics, Inc Introduction and Business Overview
7.15.3 Endoceutics, Inc Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2019-2024)
7.15.4 Endoceutics, Inc Postmenopausal Vaginal Atrophy Drugs Product Offerings
7.15.5 Endoceutics, Inc Recent Development
8 Industry Chain Analysis
8.1 Postmenopausal Vaginal Atrophy Drugs Industrial Chain
8.2 Postmenopausal Vaginal Atrophy Drugs Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Postmenopausal Vaginal Atrophy Drugs Sales Model
8.5.2 Sales Channel
8.5.3 Postmenopausal Vaginal Atrophy Drugs Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
1.1 Postmenopausal Vaginal Atrophy Drugs Product Introduction
1.2 Global Postmenopausal Vaginal Atrophy Drugs Market Size Forecast
1.2.1 Global Postmenopausal Vaginal Atrophy Drugs Sales Value (2019-2030)
1.2.2 Global Postmenopausal Vaginal Atrophy Drugs Sales Volume (2019-2030)
1.2.3 Global Postmenopausal Vaginal Atrophy Drugs Sales Price (2019-2030)
1.3 Postmenopausal Vaginal Atrophy Drugs Market Trends & Drivers
1.3.1 Postmenopausal Vaginal Atrophy Drugs Industry Trends
1.3.2 Postmenopausal Vaginal Atrophy Drugs Market Drivers & Opportunity
1.3.3 Postmenopausal Vaginal Atrophy Drugs Market Challenges
1.3.4 Postmenopausal Vaginal Atrophy Drugs Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Postmenopausal Vaginal Atrophy Drugs Players Revenue Ranking (2023)
2.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue by Company (2019-2024)
2.3 Global Postmenopausal Vaginal Atrophy Drugs Players Sales Volume Ranking (2023)
2.4 Global Postmenopausal Vaginal Atrophy Drugs Sales Volume by Company Players (2019-2024)
2.5 Global Postmenopausal Vaginal Atrophy Drugs Average Price by Company (2019-2024)
2.6 Key Manufacturers Postmenopausal Vaginal Atrophy Drugs Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Postmenopausal Vaginal Atrophy Drugs Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Postmenopausal Vaginal Atrophy Drugs
2.9 Postmenopausal Vaginal Atrophy Drugs Market Competitive Analysis
2.9.1 Postmenopausal Vaginal Atrophy Drugs Market Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by Postmenopausal Vaginal Atrophy Drugs Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Postmenopausal Vaginal Atrophy Drugs as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Topical Estrogen
3.1.2 Oral Estrogen
3.1.3 Other
3.2 Global Postmenopausal Vaginal Atrophy Drugs Sales Value by Type
3.2.1 Global Postmenopausal Vaginal Atrophy Drugs Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Postmenopausal Vaginal Atrophy Drugs Sales Value, by Type (2019-2030)
3.2.3 Global Postmenopausal Vaginal Atrophy Drugs Sales Value, by Type (%) (2019-2030)
3.3 Global Postmenopausal Vaginal Atrophy Drugs Sales Volume by Type
3.3.1 Global Postmenopausal Vaginal Atrophy Drugs Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global Postmenopausal Vaginal Atrophy Drugs Sales Volume, by Type (2019-2030)
3.3.3 Global Postmenopausal Vaginal Atrophy Drugs Sales Volume, by Type (%) (2019-2030)
3.4 Global Postmenopausal Vaginal Atrophy Drugs Average Price by Type (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Online Pharmacy
4.1.2 Hospital Pharmacy
4.2 Global Postmenopausal Vaginal Atrophy Drugs Sales Value by Application
4.2.1 Global Postmenopausal Vaginal Atrophy Drugs Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Postmenopausal Vaginal Atrophy Drugs Sales Value, by Application (2019-2030)
4.2.3 Global Postmenopausal Vaginal Atrophy Drugs Sales Value, by Application (%) (2019-2030)
4.3 Global Postmenopausal Vaginal Atrophy Drugs Sales Volume by Application
4.3.1 Global Postmenopausal Vaginal Atrophy Drugs Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global Postmenopausal Vaginal Atrophy Drugs Sales Volume, by Application (2019-2030)
4.3.3 Global Postmenopausal Vaginal Atrophy Drugs Sales Volume, by Application (%) (2019-2030)
4.4 Global Postmenopausal Vaginal Atrophy Drugs Average Price by Application (2019-2030)
5 Segmentation by Region
5.1 Global Postmenopausal Vaginal Atrophy Drugs Sales Value by Region
5.1.1 Global Postmenopausal Vaginal Atrophy Drugs Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Postmenopausal Vaginal Atrophy Drugs Sales Value by Region (2019-2024)
5.1.3 Global Postmenopausal Vaginal Atrophy Drugs Sales Value by Region (2025-2030)
5.1.4 Global Postmenopausal Vaginal Atrophy Drugs Sales Value by Region (%), (2019-2030)
5.2 Global Postmenopausal Vaginal Atrophy Drugs Sales Volume by Region
5.2.1 Global Postmenopausal Vaginal Atrophy Drugs Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global Postmenopausal Vaginal Atrophy Drugs Sales Volume by Region (2019-2024)
5.2.3 Global Postmenopausal Vaginal Atrophy Drugs Sales Volume by Region (2025-2030)
5.2.4 Global Postmenopausal Vaginal Atrophy Drugs Sales Volume by Region (%), (2019-2030)
5.3 Global Postmenopausal Vaginal Atrophy Drugs Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America Postmenopausal Vaginal Atrophy Drugs Sales Value, 2019-2030
5.4.2 North America Postmenopausal Vaginal Atrophy Drugs Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe Postmenopausal Vaginal Atrophy Drugs Sales Value, 2019-2030
5.5.2 Europe Postmenopausal Vaginal Atrophy Drugs Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific Postmenopausal Vaginal Atrophy Drugs Sales Value, 2019-2030
5.6.2 Asia Pacific Postmenopausal Vaginal Atrophy Drugs Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America Postmenopausal Vaginal Atrophy Drugs Sales Value, 2019-2030
5.7.2 South America Postmenopausal Vaginal Atrophy Drugs Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Sales Value, 2019-2030
5.8.2 Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Postmenopausal Vaginal Atrophy Drugs Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Postmenopausal Vaginal Atrophy Drugs Sales Value
6.2.1 Key Countries/Regions Postmenopausal Vaginal Atrophy Drugs Sales Value, 2019-2030
6.2.2 Key Countries/Regions Postmenopausal Vaginal Atrophy Drugs Sales Volume, 2019-2030
6.3 United States
6.3.1 United States Postmenopausal Vaginal Atrophy Drugs Sales Value, 2019-2030
6.3.2 United States Postmenopausal Vaginal Atrophy Drugs Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Postmenopausal Vaginal Atrophy Drugs Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Postmenopausal Vaginal Atrophy Drugs Sales Value, 2019-2030
6.4.2 Europe Postmenopausal Vaginal Atrophy Drugs Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Postmenopausal Vaginal Atrophy Drugs Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Postmenopausal Vaginal Atrophy Drugs Sales Value, 2019-2030
6.5.2 China Postmenopausal Vaginal Atrophy Drugs Sales Value by Type (%), 2023 VS 2030
6.5.3 China Postmenopausal Vaginal Atrophy Drugs Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Postmenopausal Vaginal Atrophy Drugs Sales Value, 2019-2030
6.6.2 Japan Postmenopausal Vaginal Atrophy Drugs Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Postmenopausal Vaginal Atrophy Drugs Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Postmenopausal Vaginal Atrophy Drugs Sales Value, 2019-2030
6.7.2 South Korea Postmenopausal Vaginal Atrophy Drugs Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Postmenopausal Vaginal Atrophy Drugs Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Postmenopausal Vaginal Atrophy Drugs Sales Value, 2019-2030
6.8.2 Southeast Asia Postmenopausal Vaginal Atrophy Drugs Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Postmenopausal Vaginal Atrophy Drugs Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Postmenopausal Vaginal Atrophy Drugs Sales Value, 2019-2030
6.9.2 India Postmenopausal Vaginal Atrophy Drugs Sales Value by Type (%), 2023 VS 2030
6.9.3 India Postmenopausal Vaginal Atrophy Drugs Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Pfizer Inc
7.1.1 Pfizer Inc Company Information
7.1.2 Pfizer Inc Introduction and Business Overview
7.1.3 Pfizer Inc Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2019-2024)
7.1.4 Pfizer Inc Postmenopausal Vaginal Atrophy Drugs Product Offerings
7.1.5 Pfizer Inc Recent Development
7.2 Mylan NV
7.2.1 Mylan NV Company Information
7.2.2 Mylan NV Introduction and Business Overview
7.2.3 Mylan NV Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2019-2024)
7.2.4 Mylan NV Postmenopausal Vaginal Atrophy Drugs Product Offerings
7.2.5 Mylan NV Recent Development
7.3 Novartis AG
7.3.1 Novartis AG Company Information
7.3.2 Novartis AG Introduction and Business Overview
7.3.3 Novartis AG Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2019-2024)
7.3.4 Novartis AG Postmenopausal Vaginal Atrophy Drugs Product Offerings
7.3.5 Novartis AG Recent Development
7.4 Hikma Pharmaceuticals plc
7.4.1 Hikma Pharmaceuticals plc Company Information
7.4.2 Hikma Pharmaceuticals plc Introduction and Business Overview
7.4.3 Hikma Pharmaceuticals plc Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2019-2024)
7.4.4 Hikma Pharmaceuticals plc Postmenopausal Vaginal Atrophy Drugs Product Offerings
7.4.5 Hikma Pharmaceuticals plc Recent Development
7.5 Aurobindo Pharma
7.5.1 Aurobindo Pharma Company Information
7.5.2 Aurobindo Pharma Introduction and Business Overview
7.5.3 Aurobindo Pharma Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2019-2024)
7.5.4 Aurobindo Pharma Postmenopausal Vaginal Atrophy Drugs Product Offerings
7.5.5 Aurobindo Pharma Recent Development
7.6 AbbVie Inc
7.6.1 AbbVie Inc Company Information
7.6.2 AbbVie Inc Introduction and Business Overview
7.6.3 AbbVie Inc Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2019-2024)
7.6.4 AbbVie Inc Postmenopausal Vaginal Atrophy Drugs Product Offerings
7.6.5 AbbVie Inc Recent Development
7.7 Melinta Therapeutics, Inc
7.7.1 Melinta Therapeutics, Inc Company Information
7.7.2 Melinta Therapeutics, Inc Introduction and Business Overview
7.7.3 Melinta Therapeutics, Inc Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2019-2024)
7.7.4 Melinta Therapeutics, Inc Postmenopausal Vaginal Atrophy Drugs Product Offerings
7.7.5 Melinta Therapeutics, Inc Recent Development
7.8 Bristol-Myers Squibb Company
7.8.1 Bristol-Myers Squibb Company Company Information
7.8.2 Bristol-Myers Squibb Company Introduction and Business Overview
7.8.3 Bristol-Myers Squibb Company Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2019-2024)
7.8.4 Bristol-Myers Squibb Company Postmenopausal Vaginal Atrophy Drugs Product Offerings
7.8.5 Bristol-Myers Squibb Company Recent Development
7.9 GSK plc
7.9.1 GSK plc Company Information
7.9.2 GSK plc Introduction and Business Overview
7.9.3 GSK plc Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2019-2024)
7.9.4 GSK plc Postmenopausal Vaginal Atrophy Drugs Product Offerings
7.9.5 GSK plc Recent Development
7.10 Bayer AG
7.10.1 Bayer AG Company Information
7.10.2 Bayer AG Introduction and Business Overview
7.10.3 Bayer AG Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2019-2024)
7.10.4 Bayer AG Postmenopausal Vaginal Atrophy Drugs Product Offerings
7.10.5 Bayer AG Recent Development
7.11 Lupin
7.11.1 Lupin Company Information
7.11.2 Lupin Introduction and Business Overview
7.11.3 Lupin Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2019-2024)
7.11.4 Lupin Postmenopausal Vaginal Atrophy Drugs Product Offerings
7.11.5 Lupin Recent Development
7.12 Perrigo Company plc
7.12.1 Perrigo Company plc Company Information
7.12.2 Perrigo Company plc Introduction and Business Overview
7.12.3 Perrigo Company plc Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2019-2024)
7.12.4 Perrigo Company plc Postmenopausal Vaginal Atrophy Drugs Product Offerings
7.12.5 Perrigo Company plc Recent Development
7.13 Bionovo, Inc
7.13.1 Bionovo, Inc Company Information
7.13.2 Bionovo, Inc Introduction and Business Overview
7.13.3 Bionovo, Inc Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2019-2024)
7.13.4 Bionovo, Inc Postmenopausal Vaginal Atrophy Drugs Product Offerings
7.13.5 Bionovo, Inc Recent Development
7.14 TherapeuticsMD, Inc
7.14.1 TherapeuticsMD, Inc Company Information
7.14.2 TherapeuticsMD, Inc Introduction and Business Overview
7.14.3 TherapeuticsMD, Inc Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2019-2024)
7.14.4 TherapeuticsMD, Inc Postmenopausal Vaginal Atrophy Drugs Product Offerings
7.14.5 TherapeuticsMD, Inc Recent Development
7.15 Endoceutics, Inc
7.15.1 Endoceutics, Inc Company Information
7.15.2 Endoceutics, Inc Introduction and Business Overview
7.15.3 Endoceutics, Inc Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2019-2024)
7.15.4 Endoceutics, Inc Postmenopausal Vaginal Atrophy Drugs Product Offerings
7.15.5 Endoceutics, Inc Recent Development
8 Industry Chain Analysis
8.1 Postmenopausal Vaginal Atrophy Drugs Industrial Chain
8.2 Postmenopausal Vaginal Atrophy Drugs Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Postmenopausal Vaginal Atrophy Drugs Sales Model
8.5.2 Sales Channel
8.5.3 Postmenopausal Vaginal Atrophy Drugs Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
List of Tables
Table 1. Postmenopausal Vaginal Atrophy Drugs Market Trends
Table 2. Postmenopausal Vaginal Atrophy Drugs Market Drivers & Opportunity
Table 3. Postmenopausal Vaginal Atrophy Drugs Market Challenges
Table 4. Postmenopausal Vaginal Atrophy Drugs Market Restraints
Table 5. Global Postmenopausal Vaginal Atrophy Drugs Revenue by Company (2019-2024) & (US$ Million)
Table 6. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Company (2019-2024)
Table 7. Global Postmenopausal Vaginal Atrophy Drugs Sales Volume by Company (2019-2024) & (K Units)
Table 8. Global Postmenopausal Vaginal Atrophy Drugs Sales Volume Market Share by Company (2019-2024)
Table 9. Global Market Postmenopausal Vaginal Atrophy Drugs Price by Company (2019-2024) & (US$/Unit)
Table 10. Key Manufacturers Postmenopausal Vaginal Atrophy Drugs Manufacturing Base Distribution and Headquarters
Table 11. Key Manufacturers Postmenopausal Vaginal Atrophy Drugs Product Type
Table 12. Key Manufacturers Time to Begin Mass Production of Postmenopausal Vaginal Atrophy Drugs
Table 13. Global Postmenopausal Vaginal Atrophy Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Postmenopausal Vaginal Atrophy Drugs as of 2023)
Table 15. Mergers & Acquisitions, Expansion Plans
Table 16. Global Postmenopausal Vaginal Atrophy Drugs Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
Table 17. Global Postmenopausal Vaginal Atrophy Drugs Sales Value by Type (2019-2024) & (US$ Million)
Table 18. Global Postmenopausal Vaginal Atrophy Drugs Sales Value by Type (2025-2030) & (US$ Million)
Table 19. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Value by Type (2019-2024) & (%)
Table 20. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Value by Type (2025-2030) & (%)
Table 21. Global Postmenopausal Vaginal Atrophy Drugs Sales Volume by Type: 2019 VS 2023 VS 2030 (K Units)
Table 22. Global Postmenopausal Vaginal Atrophy Drugs Sales Volume by Type (2019-2024) & (K Units)
Table 23. Global Postmenopausal Vaginal Atrophy Drugs Sales Volume by Type (2025-2030) & (K Units)
Table 24. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Volume by Type (2019-2024) & (%)
Table 25. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Volume by Type (2025-2030) & (%)
Table 26. Global Postmenopausal Vaginal Atrophy Drugs Price by Type (2019-2024) & (US$/Unit)
Table 27. Global Postmenopausal Vaginal Atrophy Drugs Price by Type (2025-2030) & (US$/Unit)
Table 28. Global Postmenopausal Vaginal Atrophy Drugs Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
Table 29. Global Postmenopausal Vaginal Atrophy Drugs Sales Value by Application (2019-2024) & (US$ Million)
Table 30. Global Postmenopausal Vaginal Atrophy Drugs Sales Value by Application (2025-2030) & (US$ Million)
Table 31. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Value by Application (2019-2024) & (%)
Table 32. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Value by Application (2025-2030) & (%)
Table 33. Global Postmenopausal Vaginal Atrophy Drugs Sales Volume by Application: 2019 VS 2023 VS 2030 (K Units)
Table 34. Global Postmenopausal Vaginal Atrophy Drugs Sales Volume by Application (2019-2024) & (K Units)
Table 35. Global Postmenopausal Vaginal Atrophy Drugs Sales Volume by Application (2025-2030) & (K Units)
Table 36. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Volume by Application (2019-2024) & (%)
Table 37. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Volume by Application (2025-2030) & (%)
Table 38. Global Postmenopausal Vaginal Atrophy Drugs Price by Application (2019-2024) & (US$/Unit)
Table 39. Global Postmenopausal Vaginal Atrophy Drugs Price by Application (2025-2030) & (US$/Unit)
Table 40. Global Postmenopausal Vaginal Atrophy Drugs Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Global Postmenopausal Vaginal Atrophy Drugs Sales Value by Region (2019-2024) & (US$ Million)
Table 42. Global Postmenopausal Vaginal Atrophy Drugs Sales Value by Region (2025-2030) & (US$ Million)
Table 43. Global Postmenopausal Vaginal Atrophy Drugs Sales Value by Region (2019-2024) & (%)
Table 44. Global Postmenopausal Vaginal Atrophy Drugs Sales Value by Region (2025-2030) & (%)
Table 45. Global Postmenopausal Vaginal Atrophy Drugs Sales Volume by Region (K Units): 2019 VS 2023 VS 2030
Table 46. Global Postmenopausal Vaginal Atrophy Drugs Sales Volume by Region (2019-2024) & (K Units)
Table 47. Global Postmenopausal Vaginal Atrophy Drugs Sales Volume by Region (2025-2030) & (K Units)
Table 48. Global Postmenopausal Vaginal Atrophy Drugs Sales Volume by Region (2019-2024) & (%)
Table 49. Global Postmenopausal Vaginal Atrophy Drugs Sales Volume by Region (2025-2030) & (%)
Table 50. Global Postmenopausal Vaginal Atrophy Drugs Average Price by Region (2019-2024) & (US$/Unit)
Table 51. Global Postmenopausal Vaginal Atrophy Drugs Average Price by Region (2025-2030) & (US$/Unit)
Table 52. Key Countries/Regions Postmenopausal Vaginal Atrophy Drugs Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
Table 53. Key Countries/Regions Postmenopausal Vaginal Atrophy Drugs Sales Value, (2019-2024) & (US$ Million)
Table 54. Key Countries/Regions Postmenopausal Vaginal Atrophy Drugs Sales Value, (2025-2030) & (US$ Million)
Table 55. Key Countries/Regions Postmenopausal Vaginal Atrophy Drugs Sales Volume, (2019-2024) & (K Units)
Table 56. Key Countries/Regions Postmenopausal Vaginal Atrophy Drugs Sales Volume, (2025-2030) & (K Units)
Table 57. Pfizer Inc Company Information
Table 58. Pfizer Inc Introduction and Business Overview
Table 59. Pfizer Inc Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 60. Pfizer Inc Postmenopausal Vaginal Atrophy Drugs Product Offerings
Table 61. Pfizer Inc Recent Development
Table 62. Mylan NV Company Information
Table 63. Mylan NV Introduction and Business Overview
Table 64. Mylan NV Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 65. Mylan NV Postmenopausal Vaginal Atrophy Drugs Product Offerings
Table 66. Mylan NV Recent Development
Table 67. Novartis AG Company Information
Table 68. Novartis AG Introduction and Business Overview
Table 69. Novartis AG Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 70. Novartis AG Postmenopausal Vaginal Atrophy Drugs Product Offerings
Table 71. Novartis AG Recent Development
Table 72. Hikma Pharmaceuticals plc Company Information
Table 73. Hikma Pharmaceuticals plc Introduction and Business Overview
Table 74. Hikma Pharmaceuticals plc Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 75. Hikma Pharmaceuticals plc Postmenopausal Vaginal Atrophy Drugs Product Offerings
Table 76. Hikma Pharmaceuticals plc Recent Development
Table 77. Aurobindo Pharma Company Information
Table 78. Aurobindo Pharma Introduction and Business Overview
Table 79. Aurobindo Pharma Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 80. Aurobindo Pharma Postmenopausal Vaginal Atrophy Drugs Product Offerings
Table 81. Aurobindo Pharma Recent Development
Table 82. AbbVie Inc Company Information
Table 83. AbbVie Inc Introduction and Business Overview
Table 84. AbbVie Inc Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 85. AbbVie Inc Postmenopausal Vaginal Atrophy Drugs Product Offerings
Table 86. AbbVie Inc Recent Development
Table 87. Melinta Therapeutics, Inc Company Information
Table 88. Melinta Therapeutics, Inc Introduction and Business Overview
Table 89. Melinta Therapeutics, Inc Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 90. Melinta Therapeutics, Inc Postmenopausal Vaginal Atrophy Drugs Product Offerings
Table 91. Melinta Therapeutics, Inc Recent Development
Table 92. Bristol-Myers Squibb Company Company Information
Table 93. Bristol-Myers Squibb Company Introduction and Business Overview
Table 94. Bristol-Myers Squibb Company Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 95. Bristol-Myers Squibb Company Postmenopausal Vaginal Atrophy Drugs Product Offerings
Table 96. Bristol-Myers Squibb Company Recent Development
Table 97. GSK plc Company Information
Table 98. GSK plc Introduction and Business Overview
Table 99. GSK plc Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 100. GSK plc Postmenopausal Vaginal Atrophy Drugs Product Offerings
Table 101. GSK plc Recent Development
Table 102. Bayer AG Company Information
Table 103. Bayer AG Introduction and Business Overview
Table 104. Bayer AG Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 105. Bayer AG Postmenopausal Vaginal Atrophy Drugs Product Offerings
Table 106. Bayer AG Recent Development
Table 107. Lupin Company Information
Table 108. Lupin Introduction and Business Overview
Table 109. Lupin Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 110. Lupin Postmenopausal Vaginal Atrophy Drugs Product Offerings
Table 111. Lupin Recent Development
Table 112. Perrigo Company plc Company Information
Table 113. Perrigo Company plc Introduction and Business Overview
Table 114. Perrigo Company plc Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 115. Perrigo Company plc Postmenopausal Vaginal Atrophy Drugs Product Offerings
Table 116. Perrigo Company plc Recent Development
Table 117. Bionovo, Inc Company Information
Table 118. Bionovo, Inc Introduction and Business Overview
Table 119. Bionovo, Inc Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 120. Bionovo, Inc Postmenopausal Vaginal Atrophy Drugs Product Offerings
Table 121. Bionovo, Inc Recent Development
Table 122. TherapeuticsMD, Inc Company Information
Table 123. TherapeuticsMD, Inc Introduction and Business Overview
Table 124. TherapeuticsMD, Inc Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 125. TherapeuticsMD, Inc Postmenopausal Vaginal Atrophy Drugs Product Offerings
Table 126. TherapeuticsMD, Inc Recent Development
Table 127. Endoceutics, Inc Company Information
Table 128. Endoceutics, Inc Introduction and Business Overview
Table 129. Endoceutics, Inc Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 130. Endoceutics, Inc Postmenopausal Vaginal Atrophy Drugs Product Offerings
Table 131. Endoceutics, Inc Recent Development
Table 132. Key Raw Materials Lists
Table 133. Raw Materials Key Suppliers Lists
Table 134. Postmenopausal Vaginal Atrophy Drugs Downstream Customers
Table 135. Postmenopausal Vaginal Atrophy Drugs Distributors List
Table 136. Research Programs/Design for This Report
Table 137. Key Data Information from Secondary Sources
Table 138. Key Data Information from Primary Sources
List of Figures
Figure 1. Postmenopausal Vaginal Atrophy Drugs Product Picture
Figure 2. Global Postmenopausal Vaginal Atrophy Drugs Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
Figure 3. Global Postmenopausal Vaginal Atrophy Drugs Sales Value (2019-2030) & (US$ Million)
Figure 4. Global Postmenopausal Vaginal Atrophy Drugs Sales Volume (2019-2030) & (K Units)
Figure 5. Global Postmenopausal Vaginal Atrophy Drugs Sales Price (2019-2030) & (US$/Unit)
Figure 6. Postmenopausal Vaginal Atrophy Drugs Report Years Considered
Figure 7. Global Postmenopausal Vaginal Atrophy Drugs Players Revenue Ranking (2023) & (US$ Million)
Figure 8. Global Postmenopausal Vaginal Atrophy Drugs Players Sales Volume Ranking (2023) & (K Units)
Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Postmenopausal Vaginal Atrophy Drugs Revenue in 2023
Figure 10. Postmenopausal Vaginal Atrophy Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 11. Topical Estrogen Picture
Figure 12. Oral Estrogen Picture
Figure 13. Other Picture
Figure 14. Global Postmenopausal Vaginal Atrophy Drugs Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 15. Global Postmenopausal Vaginal Atrophy Drugs Sales Value Market Share by Type, 2023 & 2030
Figure 16. Global Postmenopausal Vaginal Atrophy Drugs Sales Volume by Type (2019 VS 2023 VS 2030) & (K Units)
Figure 17. Global Postmenopausal Vaginal Atrophy Drugs Sales Volume Market Share by Type, 2023 & 2030
Figure 18. Global Postmenopausal Vaginal Atrophy Drugs Price by Type (2019-2030) & (US$/Unit)
Figure 19. Product Picture of Online Pharmacy
Figure 20. Product Picture of Hospital Pharmacy
Figure 21. Global Postmenopausal Vaginal Atrophy Drugs Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 22. Global Postmenopausal Vaginal Atrophy Drugs Sales Value Market Share by Application, 2023 & 2030
Figure 23. Global Postmenopausal Vaginal Atrophy Drugs Sales Volume by Application (2019 VS 2023 VS 2030) & (K Units)
Figure 24. Global Postmenopausal Vaginal Atrophy Drugs Sales Volume Market Share by Application, 2023 & 2030
Figure 25. Global Postmenopausal Vaginal Atrophy Drugs Price by Application (2019-2030) & (US$/Unit)
Figure 26. North America Postmenopausal Vaginal Atrophy Drugs Sales Value (2019-2030) & (US$ Million)
Figure 27. North America Postmenopausal Vaginal Atrophy Drugs Sales Value by Country (%), 2023 VS 2030
Figure 28. Europe Postmenopausal Vaginal Atrophy Drugs Sales Value (2019-2030) & (US$ Million)
Figure 29. Europe Postmenopausal Vaginal Atrophy Drugs Sales Value by Country (%), 2023 VS 2030
Figure 30. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Sales Value (2019-2030) & (US$ Million)
Figure 31. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Sales Value by Country (%), 2023 VS 2030
Figure 32. South America Postmenopausal Vaginal Atrophy Drugs Sales Value (2019-2030) & (US$ Million)
Figure 33. South America Postmenopausal Vaginal Atrophy Drugs Sales Value by Country (%), 2023 VS 2030
Figure 34. Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Sales Value (2019-2030) & (US$ Million)
Figure 35. Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Sales Value by Country (%), 2023 VS 2030
Figure 36. Key Countries/Regions Postmenopausal Vaginal Atrophy Drugs Sales Value (%), (2019-2030)
Figure 37. Key Countries/Regions Postmenopausal Vaginal Atrophy Drugs Sales Volume (%), (2019-2030)
Figure 38. United States Postmenopausal Vaginal Atrophy Drugs Sales Value, (2019-2030) & (US$ Million)
Figure 39. United States Postmenopausal Vaginal Atrophy Drugs Sales Value by Type (%), 2023 VS 2030
Figure 40. United States Postmenopausal Vaginal Atrophy Drugs Sales Value by Application (%), 2023 VS 2030
Figure 41. Europe Postmenopausal Vaginal Atrophy Drugs Sales Value, (2019-2030) & (US$ Million)
Figure 42. Europe Postmenopausal Vaginal Atrophy Drugs Sales Value by Type (%), 2023 VS 2030
Figure 43. Europe Postmenopausal Vaginal Atrophy Drugs Sales Value by Application (%), 2023 VS 2030
Figure 44. China Postmenopausal Vaginal Atrophy Drugs Sales Value, (2019-2030) & (US$ Million)
Figure 45. China Postmenopausal Vaginal Atrophy Drugs Sales Value by Type (%), 2023 VS 2030
Figure 46. China Postmenopausal Vaginal Atrophy Drugs Sales Value by Application (%), 2023 VS 2030
Figure 47. Japan Postmenopausal Vaginal Atrophy Drugs Sales Value, (2019-2030) & (US$ Million)
Figure 48. Japan Postmenopausal Vaginal Atrophy Drugs Sales Value by Type (%), 2023 VS 2030
Figure 49. Japan Postmenopausal Vaginal Atrophy Drugs Sales Value by Application (%), 2023 VS 2030
Figure 50. South Korea Postmenopausal Vaginal Atrophy Drugs Sales Value, (2019-2030) & (US$ Million)
Figure 51. South Korea Postmenopausal Vaginal Atrophy Drugs Sales Value by Type (%), 2023 VS 2030
Figure 52. South Korea Postmenopausal Vaginal Atrophy Drugs Sales Value by Application (%), 2023 VS 2030
Figure 53. Southeast Asia Postmenopausal Vaginal Atrophy Drugs Sales Value, (2019-2030) & (US$ Million)
Figure 54. Southeast Asia Postmenopausal Vaginal Atrophy Drugs Sales Value by Type (%), 2023 VS 2030
Figure 55. Southeast Asia Postmenopausal Vaginal Atrophy Drugs Sales Value by Application (%), 2023 VS 2030
Figure 56. India Postmenopausal Vaginal Atrophy Drugs Sales Value, (2019-2030) & (US$ Million)
Figure 57. India Postmenopausal Vaginal Atrophy Drugs Sales Value by Type (%), 2023 VS 2030
Figure 58. India Postmenopausal Vaginal Atrophy Drugs Sales Value by Application (%), 2023 VS 2030
Figure 59. Postmenopausal Vaginal Atrophy Drugs Industrial Chain
Figure 60. Postmenopausal Vaginal Atrophy Drugs Manufacturing Cost Structure
Figure 61. Channels of Distribution (Direct Sales, and Distribution)
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed
Table 1. Postmenopausal Vaginal Atrophy Drugs Market Trends
Table 2. Postmenopausal Vaginal Atrophy Drugs Market Drivers & Opportunity
Table 3. Postmenopausal Vaginal Atrophy Drugs Market Challenges
Table 4. Postmenopausal Vaginal Atrophy Drugs Market Restraints
Table 5. Global Postmenopausal Vaginal Atrophy Drugs Revenue by Company (2019-2024) & (US$ Million)
Table 6. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Company (2019-2024)
Table 7. Global Postmenopausal Vaginal Atrophy Drugs Sales Volume by Company (2019-2024) & (K Units)
Table 8. Global Postmenopausal Vaginal Atrophy Drugs Sales Volume Market Share by Company (2019-2024)
Table 9. Global Market Postmenopausal Vaginal Atrophy Drugs Price by Company (2019-2024) & (US$/Unit)
Table 10. Key Manufacturers Postmenopausal Vaginal Atrophy Drugs Manufacturing Base Distribution and Headquarters
Table 11. Key Manufacturers Postmenopausal Vaginal Atrophy Drugs Product Type
Table 12. Key Manufacturers Time to Begin Mass Production of Postmenopausal Vaginal Atrophy Drugs
Table 13. Global Postmenopausal Vaginal Atrophy Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Postmenopausal Vaginal Atrophy Drugs as of 2023)
Table 15. Mergers & Acquisitions, Expansion Plans
Table 16. Global Postmenopausal Vaginal Atrophy Drugs Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
Table 17. Global Postmenopausal Vaginal Atrophy Drugs Sales Value by Type (2019-2024) & (US$ Million)
Table 18. Global Postmenopausal Vaginal Atrophy Drugs Sales Value by Type (2025-2030) & (US$ Million)
Table 19. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Value by Type (2019-2024) & (%)
Table 20. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Value by Type (2025-2030) & (%)
Table 21. Global Postmenopausal Vaginal Atrophy Drugs Sales Volume by Type: 2019 VS 2023 VS 2030 (K Units)
Table 22. Global Postmenopausal Vaginal Atrophy Drugs Sales Volume by Type (2019-2024) & (K Units)
Table 23. Global Postmenopausal Vaginal Atrophy Drugs Sales Volume by Type (2025-2030) & (K Units)
Table 24. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Volume by Type (2019-2024) & (%)
Table 25. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Volume by Type (2025-2030) & (%)
Table 26. Global Postmenopausal Vaginal Atrophy Drugs Price by Type (2019-2024) & (US$/Unit)
Table 27. Global Postmenopausal Vaginal Atrophy Drugs Price by Type (2025-2030) & (US$/Unit)
Table 28. Global Postmenopausal Vaginal Atrophy Drugs Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
Table 29. Global Postmenopausal Vaginal Atrophy Drugs Sales Value by Application (2019-2024) & (US$ Million)
Table 30. Global Postmenopausal Vaginal Atrophy Drugs Sales Value by Application (2025-2030) & (US$ Million)
Table 31. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Value by Application (2019-2024) & (%)
Table 32. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Value by Application (2025-2030) & (%)
Table 33. Global Postmenopausal Vaginal Atrophy Drugs Sales Volume by Application: 2019 VS 2023 VS 2030 (K Units)
Table 34. Global Postmenopausal Vaginal Atrophy Drugs Sales Volume by Application (2019-2024) & (K Units)
Table 35. Global Postmenopausal Vaginal Atrophy Drugs Sales Volume by Application (2025-2030) & (K Units)
Table 36. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Volume by Application (2019-2024) & (%)
Table 37. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Volume by Application (2025-2030) & (%)
Table 38. Global Postmenopausal Vaginal Atrophy Drugs Price by Application (2019-2024) & (US$/Unit)
Table 39. Global Postmenopausal Vaginal Atrophy Drugs Price by Application (2025-2030) & (US$/Unit)
Table 40. Global Postmenopausal Vaginal Atrophy Drugs Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Global Postmenopausal Vaginal Atrophy Drugs Sales Value by Region (2019-2024) & (US$ Million)
Table 42. Global Postmenopausal Vaginal Atrophy Drugs Sales Value by Region (2025-2030) & (US$ Million)
Table 43. Global Postmenopausal Vaginal Atrophy Drugs Sales Value by Region (2019-2024) & (%)
Table 44. Global Postmenopausal Vaginal Atrophy Drugs Sales Value by Region (2025-2030) & (%)
Table 45. Global Postmenopausal Vaginal Atrophy Drugs Sales Volume by Region (K Units): 2019 VS 2023 VS 2030
Table 46. Global Postmenopausal Vaginal Atrophy Drugs Sales Volume by Region (2019-2024) & (K Units)
Table 47. Global Postmenopausal Vaginal Atrophy Drugs Sales Volume by Region (2025-2030) & (K Units)
Table 48. Global Postmenopausal Vaginal Atrophy Drugs Sales Volume by Region (2019-2024) & (%)
Table 49. Global Postmenopausal Vaginal Atrophy Drugs Sales Volume by Region (2025-2030) & (%)
Table 50. Global Postmenopausal Vaginal Atrophy Drugs Average Price by Region (2019-2024) & (US$/Unit)
Table 51. Global Postmenopausal Vaginal Atrophy Drugs Average Price by Region (2025-2030) & (US$/Unit)
Table 52. Key Countries/Regions Postmenopausal Vaginal Atrophy Drugs Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
Table 53. Key Countries/Regions Postmenopausal Vaginal Atrophy Drugs Sales Value, (2019-2024) & (US$ Million)
Table 54. Key Countries/Regions Postmenopausal Vaginal Atrophy Drugs Sales Value, (2025-2030) & (US$ Million)
Table 55. Key Countries/Regions Postmenopausal Vaginal Atrophy Drugs Sales Volume, (2019-2024) & (K Units)
Table 56. Key Countries/Regions Postmenopausal Vaginal Atrophy Drugs Sales Volume, (2025-2030) & (K Units)
Table 57. Pfizer Inc Company Information
Table 58. Pfizer Inc Introduction and Business Overview
Table 59. Pfizer Inc Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 60. Pfizer Inc Postmenopausal Vaginal Atrophy Drugs Product Offerings
Table 61. Pfizer Inc Recent Development
Table 62. Mylan NV Company Information
Table 63. Mylan NV Introduction and Business Overview
Table 64. Mylan NV Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 65. Mylan NV Postmenopausal Vaginal Atrophy Drugs Product Offerings
Table 66. Mylan NV Recent Development
Table 67. Novartis AG Company Information
Table 68. Novartis AG Introduction and Business Overview
Table 69. Novartis AG Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 70. Novartis AG Postmenopausal Vaginal Atrophy Drugs Product Offerings
Table 71. Novartis AG Recent Development
Table 72. Hikma Pharmaceuticals plc Company Information
Table 73. Hikma Pharmaceuticals plc Introduction and Business Overview
Table 74. Hikma Pharmaceuticals plc Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 75. Hikma Pharmaceuticals plc Postmenopausal Vaginal Atrophy Drugs Product Offerings
Table 76. Hikma Pharmaceuticals plc Recent Development
Table 77. Aurobindo Pharma Company Information
Table 78. Aurobindo Pharma Introduction and Business Overview
Table 79. Aurobindo Pharma Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 80. Aurobindo Pharma Postmenopausal Vaginal Atrophy Drugs Product Offerings
Table 81. Aurobindo Pharma Recent Development
Table 82. AbbVie Inc Company Information
Table 83. AbbVie Inc Introduction and Business Overview
Table 84. AbbVie Inc Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 85. AbbVie Inc Postmenopausal Vaginal Atrophy Drugs Product Offerings
Table 86. AbbVie Inc Recent Development
Table 87. Melinta Therapeutics, Inc Company Information
Table 88. Melinta Therapeutics, Inc Introduction and Business Overview
Table 89. Melinta Therapeutics, Inc Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 90. Melinta Therapeutics, Inc Postmenopausal Vaginal Atrophy Drugs Product Offerings
Table 91. Melinta Therapeutics, Inc Recent Development
Table 92. Bristol-Myers Squibb Company Company Information
Table 93. Bristol-Myers Squibb Company Introduction and Business Overview
Table 94. Bristol-Myers Squibb Company Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 95. Bristol-Myers Squibb Company Postmenopausal Vaginal Atrophy Drugs Product Offerings
Table 96. Bristol-Myers Squibb Company Recent Development
Table 97. GSK plc Company Information
Table 98. GSK plc Introduction and Business Overview
Table 99. GSK plc Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 100. GSK plc Postmenopausal Vaginal Atrophy Drugs Product Offerings
Table 101. GSK plc Recent Development
Table 102. Bayer AG Company Information
Table 103. Bayer AG Introduction and Business Overview
Table 104. Bayer AG Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 105. Bayer AG Postmenopausal Vaginal Atrophy Drugs Product Offerings
Table 106. Bayer AG Recent Development
Table 107. Lupin Company Information
Table 108. Lupin Introduction and Business Overview
Table 109. Lupin Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 110. Lupin Postmenopausal Vaginal Atrophy Drugs Product Offerings
Table 111. Lupin Recent Development
Table 112. Perrigo Company plc Company Information
Table 113. Perrigo Company plc Introduction and Business Overview
Table 114. Perrigo Company plc Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 115. Perrigo Company plc Postmenopausal Vaginal Atrophy Drugs Product Offerings
Table 116. Perrigo Company plc Recent Development
Table 117. Bionovo, Inc Company Information
Table 118. Bionovo, Inc Introduction and Business Overview
Table 119. Bionovo, Inc Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 120. Bionovo, Inc Postmenopausal Vaginal Atrophy Drugs Product Offerings
Table 121. Bionovo, Inc Recent Development
Table 122. TherapeuticsMD, Inc Company Information
Table 123. TherapeuticsMD, Inc Introduction and Business Overview
Table 124. TherapeuticsMD, Inc Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 125. TherapeuticsMD, Inc Postmenopausal Vaginal Atrophy Drugs Product Offerings
Table 126. TherapeuticsMD, Inc Recent Development
Table 127. Endoceutics, Inc Company Information
Table 128. Endoceutics, Inc Introduction and Business Overview
Table 129. Endoceutics, Inc Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 130. Endoceutics, Inc Postmenopausal Vaginal Atrophy Drugs Product Offerings
Table 131. Endoceutics, Inc Recent Development
Table 132. Key Raw Materials Lists
Table 133. Raw Materials Key Suppliers Lists
Table 134. Postmenopausal Vaginal Atrophy Drugs Downstream Customers
Table 135. Postmenopausal Vaginal Atrophy Drugs Distributors List
Table 136. Research Programs/Design for This Report
Table 137. Key Data Information from Secondary Sources
Table 138. Key Data Information from Primary Sources
List of Figures
Figure 1. Postmenopausal Vaginal Atrophy Drugs Product Picture
Figure 2. Global Postmenopausal Vaginal Atrophy Drugs Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
Figure 3. Global Postmenopausal Vaginal Atrophy Drugs Sales Value (2019-2030) & (US$ Million)
Figure 4. Global Postmenopausal Vaginal Atrophy Drugs Sales Volume (2019-2030) & (K Units)
Figure 5. Global Postmenopausal Vaginal Atrophy Drugs Sales Price (2019-2030) & (US$/Unit)
Figure 6. Postmenopausal Vaginal Atrophy Drugs Report Years Considered
Figure 7. Global Postmenopausal Vaginal Atrophy Drugs Players Revenue Ranking (2023) & (US$ Million)
Figure 8. Global Postmenopausal Vaginal Atrophy Drugs Players Sales Volume Ranking (2023) & (K Units)
Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Postmenopausal Vaginal Atrophy Drugs Revenue in 2023
Figure 10. Postmenopausal Vaginal Atrophy Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 11. Topical Estrogen Picture
Figure 12. Oral Estrogen Picture
Figure 13. Other Picture
Figure 14. Global Postmenopausal Vaginal Atrophy Drugs Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 15. Global Postmenopausal Vaginal Atrophy Drugs Sales Value Market Share by Type, 2023 & 2030
Figure 16. Global Postmenopausal Vaginal Atrophy Drugs Sales Volume by Type (2019 VS 2023 VS 2030) & (K Units)
Figure 17. Global Postmenopausal Vaginal Atrophy Drugs Sales Volume Market Share by Type, 2023 & 2030
Figure 18. Global Postmenopausal Vaginal Atrophy Drugs Price by Type (2019-2030) & (US$/Unit)
Figure 19. Product Picture of Online Pharmacy
Figure 20. Product Picture of Hospital Pharmacy
Figure 21. Global Postmenopausal Vaginal Atrophy Drugs Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 22. Global Postmenopausal Vaginal Atrophy Drugs Sales Value Market Share by Application, 2023 & 2030
Figure 23. Global Postmenopausal Vaginal Atrophy Drugs Sales Volume by Application (2019 VS 2023 VS 2030) & (K Units)
Figure 24. Global Postmenopausal Vaginal Atrophy Drugs Sales Volume Market Share by Application, 2023 & 2030
Figure 25. Global Postmenopausal Vaginal Atrophy Drugs Price by Application (2019-2030) & (US$/Unit)
Figure 26. North America Postmenopausal Vaginal Atrophy Drugs Sales Value (2019-2030) & (US$ Million)
Figure 27. North America Postmenopausal Vaginal Atrophy Drugs Sales Value by Country (%), 2023 VS 2030
Figure 28. Europe Postmenopausal Vaginal Atrophy Drugs Sales Value (2019-2030) & (US$ Million)
Figure 29. Europe Postmenopausal Vaginal Atrophy Drugs Sales Value by Country (%), 2023 VS 2030
Figure 30. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Sales Value (2019-2030) & (US$ Million)
Figure 31. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Sales Value by Country (%), 2023 VS 2030
Figure 32. South America Postmenopausal Vaginal Atrophy Drugs Sales Value (2019-2030) & (US$ Million)
Figure 33. South America Postmenopausal Vaginal Atrophy Drugs Sales Value by Country (%), 2023 VS 2030
Figure 34. Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Sales Value (2019-2030) & (US$ Million)
Figure 35. Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Sales Value by Country (%), 2023 VS 2030
Figure 36. Key Countries/Regions Postmenopausal Vaginal Atrophy Drugs Sales Value (%), (2019-2030)
Figure 37. Key Countries/Regions Postmenopausal Vaginal Atrophy Drugs Sales Volume (%), (2019-2030)
Figure 38. United States Postmenopausal Vaginal Atrophy Drugs Sales Value, (2019-2030) & (US$ Million)
Figure 39. United States Postmenopausal Vaginal Atrophy Drugs Sales Value by Type (%), 2023 VS 2030
Figure 40. United States Postmenopausal Vaginal Atrophy Drugs Sales Value by Application (%), 2023 VS 2030
Figure 41. Europe Postmenopausal Vaginal Atrophy Drugs Sales Value, (2019-2030) & (US$ Million)
Figure 42. Europe Postmenopausal Vaginal Atrophy Drugs Sales Value by Type (%), 2023 VS 2030
Figure 43. Europe Postmenopausal Vaginal Atrophy Drugs Sales Value by Application (%), 2023 VS 2030
Figure 44. China Postmenopausal Vaginal Atrophy Drugs Sales Value, (2019-2030) & (US$ Million)
Figure 45. China Postmenopausal Vaginal Atrophy Drugs Sales Value by Type (%), 2023 VS 2030
Figure 46. China Postmenopausal Vaginal Atrophy Drugs Sales Value by Application (%), 2023 VS 2030
Figure 47. Japan Postmenopausal Vaginal Atrophy Drugs Sales Value, (2019-2030) & (US$ Million)
Figure 48. Japan Postmenopausal Vaginal Atrophy Drugs Sales Value by Type (%), 2023 VS 2030
Figure 49. Japan Postmenopausal Vaginal Atrophy Drugs Sales Value by Application (%), 2023 VS 2030
Figure 50. South Korea Postmenopausal Vaginal Atrophy Drugs Sales Value, (2019-2030) & (US$ Million)
Figure 51. South Korea Postmenopausal Vaginal Atrophy Drugs Sales Value by Type (%), 2023 VS 2030
Figure 52. South Korea Postmenopausal Vaginal Atrophy Drugs Sales Value by Application (%), 2023 VS 2030
Figure 53. Southeast Asia Postmenopausal Vaginal Atrophy Drugs Sales Value, (2019-2030) & (US$ Million)
Figure 54. Southeast Asia Postmenopausal Vaginal Atrophy Drugs Sales Value by Type (%), 2023 VS 2030
Figure 55. Southeast Asia Postmenopausal Vaginal Atrophy Drugs Sales Value by Application (%), 2023 VS 2030
Figure 56. India Postmenopausal Vaginal Atrophy Drugs Sales Value, (2019-2030) & (US$ Million)
Figure 57. India Postmenopausal Vaginal Atrophy Drugs Sales Value by Type (%), 2023 VS 2030
Figure 58. India Postmenopausal Vaginal Atrophy Drugs Sales Value by Application (%), 2023 VS 2030
Figure 59. Postmenopausal Vaginal Atrophy Drugs Industrial Chain
Figure 60. Postmenopausal Vaginal Atrophy Drugs Manufacturing Cost Structure
Figure 61. Channels of Distribution (Direct Sales, and Distribution)
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Digital Multifunction Meter - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Oct 12, 24
Whole Current Energy Meter - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Oct 12, 24
High Current Air Circuit Breaker - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Oct 12, 24
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232